Current approved therapeutic strategies for IPF and LC treatment.
By A Mystery Man Writer
Current approved therapeutic strategies for IPF and LC treatment
Patient recruitment flow chart. Abbreviation: LC-IPF = lung cancer
Roberto TONELLI, Professor (Assistant), MD PhD, University Hospital of Modena, Respiratory Diseases Unit Centre for Rare Lung Diseases, Experimental Pnuemology Laboratory Dpt of Medical and Surgical Sciences
Georgina COLÓ, PhD, PhD, Biología del Cáncer
Treatment outcomes of patients with stage III non–small cell lung
Overview of Idiopathic Pulmonary Fibrosis, Evidence-Based
Frontiers The Selective Angiotensin II Type 2 Receptor Agonist
A comprehensive comparison of the safety and efficacy of drugs in
Roberto TONELLI, Professor (Assistant), MD PhD, University Hospital of Modena, Respiratory Diseases Unit Centre for Rare Lung Diseases, Experimental Pnuemology Laboratory Dpt of Medical and Surgical Sciences
Frontiers Potential targeted therapy based on deep insight into
Pie chart of modified MRC dyspnea score of chILD in Egyptian patients
Frontiers Sarcoidosis: Updates on therapeutic drug trials and
The oncogenic landscape of the idiopathic pulmonary fibrosis: a
Fibroblast-enriched endoplasmic reticulum protein TXNDC5 promotes
